CG
NVAX icon

Carmignac Gestion’s Novavax NVAX Stock Holding History

Carmignac Gestion’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-457,805
Closed -$97.2M – 133
2021
Q2 		$97.2M Sell
457,805
-71,364
-13% -$13.1M 1.13% 28
2021
Q1 		$95.9M Buy
+529,169
New +$105M 1.1% 35

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Carmignac Gestion's NVAX Position: Q3 2021 in Review

Carmignac Gestion sold out of Novavax (NVAX) in Q3 2021, closing a stake of 457,805 shares — an estimated $97.2M sold.

Carmignac Gestion first reported a position in NVAX in Q1 2021 and held it in 2 quarters. The position peaked at $97.2M in Q2 2021. 442 funds tracked by Wall St. Rank hold NVAX as of Q3 2021.

  • Carmignac Gestion reported no remaining Novavax position as of Q3 2021 after selling out during the quarter.
  • Carmignac Gestion sold 457,805 Novavax shares in Q3 2021, an estimated $97.2M.
  • Carmignac Gestion first reported a position in Novavax in Q1 2021 and held it in 2 quarters.
  • Carmignac Gestion's Novavax position peaked at $97.2M in Q2 2021.
  • 442 funds tracked by Wall St. Rank held Novavax as of Q3 2021.

Based on Carmignac Gestion's 13F filing for Q3 2021, filed 12 Nov 2021.